Prognostic significance of cortactin levels in head and neck squamous cell carcinoma: comparison with epidermal growth factor receptor status

[1]  J. Condeelis,et al.  Regulation of the actin cytoskeleton in cancer cell migration and invasion. , 2007, Biochimica et biophysica acta.

[2]  K. Kok,et al.  High-resolution mapping identifies a commonly amplified 11q13.3 region containing multiple genes flanked by segmental duplications , 2007, Human Genetics.

[3]  M. Morgan,et al.  Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck , 2007, British Journal of Cancer.

[4]  Q. Zhan,et al.  Amplification and overexpression of CTTN (EMS1) contribute to the metastasis of esophageal squamous cell carcinoma by promoting cell migration and anoikis resistance. , 2006, Cancer research.

[5]  T. Godfrey,et al.  Comprehensive genome and transcriptome analysis of the 11q13 amplicon in human oral cancer and synteny to the 7F5 amplicon in murine oral carcinoma , 2006, Genes, chromosomes & cancer.

[6]  A. Ouhtit,et al.  Cortactin underpins CD44-promoted invasion and adhesion of breast cancer cells to bone marrow endothelial cells , 2006, Oncogene.

[7]  Jennifer L Hunt,et al.  Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting , 2006, Clinical Cancer Research.

[8]  P. Harari,et al.  Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer , 2006, Expert review of anticancer therapy.

[9]  S. Weed,et al.  Cortactin overexpression regulates actin-related protein 2/3 complex activity, motility, and invasion in carcinomas with chromosome 11q13 amplification. , 2006, Cancer research.

[10]  Larry Norton,et al.  Is cancer a disease of self-seeding? , 2006, Nature Medicine.

[11]  J. Grandis,et al.  Epidermal growth factor receptor biology in head and neck cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  H. Hosaka,et al.  Targeting AMAP1 and cortactin binding bearing an atypical src homology 3/proline interface for prevention of breast cancer invasion and metastasis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[13]  John Condeelis,et al.  Invadopodia and podosomes in tumor invasion. , 2006, European journal of cell biology.

[14]  Françoise Seillier-Moiseiwitsch,et al.  Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: defining the stages of invadopodia formation and function. , 2006, Cancer research.

[15]  P. Lichter,et al.  Recurrent coamplification of cytoskeleton‐associated genes EMS1 and SHANK2 with CCND1 in oral squamous cell carcinoma , 2006, Genes, chromosomes & cancer.

[16]  Z. Trajanoski,et al.  Effector memory T cells, early metastasis, and survival in colorectal cancer. , 2005, The New England journal of medicine.

[17]  T. Helliwell,et al.  Tissue microarray of head and neck squamous carcinoma: validation of the methodology for the study of cutaneous fatty acid-binding protein, vascular endothelial growth factor, involucrin and Ki-67 , 2005, Virchows Archiv.

[18]  A. D. Dei Tos,et al.  Assessing epidermal growth factor receptor expression in tumours: what is the value of current test methods? , 2005, European journal of cancer.

[19]  P. Timpson,et al.  Cortactin overexpression inhibits ligand-induced down-regulation of the epidermal growth factor receptor. , 2005, Cancer research.

[20]  Tsutomu Ohta,et al.  Overexpression of cortactin is involved in motility and metastasis of hepatocellular carcinoma. , 2004, Journal of hepatology.

[21]  R. Daly.  Cortactin signalling and dynamic actin networks. , 2004, The Biochemical journal.

[22]  C. J. Barnes,et al.  The Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 (Iressa) Suppresses c-Src and Pak1 Pathways and Invasiveness of Human Cancer Cells , 2004, Clinical Cancer Research.

[23]  J. Grandis,et al.  Src Kinases Mediate STAT Growth Pathways in Squamous Cell Carcinoma of the Head and Neck* , 2003, Journal of Biological Chemistry.

[24]  G. Corthals,et al.  A Cortactin-CD2-associated Protein (CD2AP) Complex Provides a Novel Link between Epidermal Growth Factor Receptor Endocytosis and the Actin Cytoskeleton* , 2003, Journal of Biological Chemistry.

[25]  Xin Huang,et al.  High-resolution mapping of the 11q13 amplicon and identification of a gene, TAOS1, that is amplified and overexpressed in oral cancer cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[26]  S. Weed,et al.  Cortactin: coupling membrane dynamics to cortical actin assembly , 2001, Oncogene.

[27]  Axel Hoos,et al.  Tissue Microarray Profiling of Cancer Specimens and Cell Lines: Opportunities and Limitations , 2001, Laboratory Investigation.

[28]  C. Haudenschild,et al.  Cortactin potentiates bone metastasis of breast cancer cells. , 2001, Cancer research.

[29]  M. McNiven,et al.  Regulated Interactions between Dynamin and the Actin-Binding Protein Cortactin Modulate Cell Shape , 2000, The Journal of cell biology.

[30]  J. Rodrigo,et al.  EMS1 gene amplification correlates with poor prognosis in squamous cell carcinomas of the head and neck. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  E. Schuuring.  The involvement of the chromosome 11q13 region in human malignancies: cyclin D1 and EMS1 are two new candidate oncogenes--a review. , 1995, Gene.

[32]  A. Bridges,et al.  A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. , 1994, Science.

[33]  F Demard,et al.  Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Grandis,et al.  Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. , 1993, Cancer research.

[35]  E. Schuuring,et al.  Amplified region of chromosome band 11q13 in breast and squamous cell carcinomas encompasses three CpG islands telomeric of FGF3, including the expressed gene EMS1 , 1993, Genes, chromosomes & cancer.

[36]  W. Blot,et al.  Second primary tumors in patients with oral cancer , 1992, Cancer.

[37]  P. Harari,et al.  EGFR-targeting monoclonal antibodies in head and neck cancer. , 2006, Current cancer drug targets.

[38]  Taylor Murray,et al.  Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.

[39]  S. Taylor.  Head and neck cancer. , 1991, Cancer chemotherapy and biological response modifiers.

[40]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.